Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Kern, Matthias ^a   Klöting, Nora ^a   Niessen, Heiko G ^b   Thomas, Leo ^b   Stiller, Detlef ^b   Mark, Michael ^b   Klein, Thomas ^b   Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; DIPEPTIDYL PEPTIDASE IV; FAS ANTIGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LINAGLIPTIN; MESSENGER RNA; PLACEBO; PROTEIN TYROSINE PHOSPHATASE 1B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DIET INDUCED OBESITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HEART; INSULIN SENSITIVITY; KIDNEY PARENCHYMA; LIPID DIET; LIVER; MACROPHAGE; MOUSE; MUSCLE TISSUE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; STEADY STATE;

ADIPOSE TISSUE; ANIMALS; DIET; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY LIVER; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PURINES; QUINAZOLINES;

EID: 84862692484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038744     Document Type: Article

References (35)

1. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
2. Nauck MA, (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124: S3-S18.
3. Vilsbøll T, Holst JJ, (2004) Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47: 357-366.
4. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, et al. (2011) The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13: 542-550.
5. Kim W, Egan JM, (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470-512.
6. Holst JJ, Gromada J, (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287: E199-E206.
7. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W, (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52.
8. Ahrén B, (2007) Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30: 1344-1350.
9. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158.
10. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, et al. (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47: 806-815.
11. Brubaker PL, Drucker DJ, (2004) Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659.
12. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, et al. (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748.
13. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, et al. (2002) Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29: 347-360.
14. Deacon CF, Holst JJ, (2010) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19: 133-140.
15. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, et al. (2008) (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325: 175-182.
16. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W, (2009) Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 61: 55-62.
17. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K, (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38: 667-678.
18. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, et al. (2009) Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 11: 786-794.
19. Scheen AJ, (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12: 648-658.
20. Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, (2008) Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 459-464.
21. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, et al. (2011) Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 120: 73-80.
22. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, et al. (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51: 943-50.
23. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, et al. (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246-1257.
24. Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, et al. (2010) Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet 6: e1000938.
25. Provencher SW, (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
26. Scott LJ, (2011) Linagliptin: in type 2 diabetes mellitus. Drugs 71: 611-624.
27. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, et al. (2011) Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13: 258-267.
28. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, et al. (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13: 65-74.
29. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA, (2011) Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 13: 653-661.
30. Matthaei S, Stumvoll M, Kellerer M, Häring HU, (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21: 585-618.
31. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G, (2010) Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 16: 1941-1951.
32. Roden M, (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348.
33. Yki-Järvinen H, (2009) Thiazolidinediones and the liver in humans. Curr Opin Lipidol 20: 477-483.
34. González-Rodríguez A, Más-Gutierrez JA, Mirasierra M, Fernandez-Pérez A, Lee YJ, et al. (2012) Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell 11: 284-296.
35. Sachithanandan N, Fam BC, Fynch S, Dzamko N, Watt MJ, et al. (2010) Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Hepatology 52: 1632-1642.